DNP+ works to ensure equitable access to treatment by advocating for reforms in intellectual property (IP) laws and policies and by building capacity and awareness around treatment rights.
DNP+ has a long-standing presence in India, engaging in patent law reform, free trade agreement (FTA) advocacy, IP-treatment literacy, capacity building, and strategic dialogue with both the government and media.
In India, DNP+ played a key role in successfully opposing patent on pediatric bedaquiline, leading to its rejection in July 2024. Additionally, DNP+ played and important role campaigning on the India-EFTA trade deal’s impact on medicine access, leading to the removal of data exclusivity provisions from the final TEPA agreement signed in March 2024.